The association of Revlimid® (lenalidomide) with venous and arterial thromboembolic events

Celgene, in consultation with the Health Sciences Authority, wishes to inform you that there is an update to the Revlimid® package insert for Singapore. Multiple myeloma patients treated with lenalidomide in combination with dexamethasone have an increased risk of venous and arterial thromboembolic events. Patients should be closely monitored with regard to these risks and action should be taken to try to minimise all modifiable risk factors for thromboembolic events. Erythropoietic agents, or other agents that may increase the risk of thromboembolism, should be used with caution. Prophylactic antithrombotic medications should be recommended, especially in patients with additional thrombotic risk factors. The decision to take antithrombotic prophylactic measures should be made after careful assessment of an individual patients' underlying risk factors.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.